Workflow
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
ALNYAlnylam Pharmaceuticals(ALNY) Zacks Investment Research·2024-02-16 18:11

Alnylam Pharmaceuticals (ALNY) reported a loss of 1.10pershareinthefourthquarterof2023,narrowerthantheZacksConsensusEstimateofalossof1.10 per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 1.20. The company had incurred a loss of 1.68pershareintheyear−agoquarter.Thefourth−quarterlossincludedstock−basedcompensationexpenses,unrealizedgainonequitysecuritiesandlossonextinguishmentofdebt.Excludingtheseitems,theadjustedlosswas77centspershare,narrowerthantheadjustedlossof1.68 per share in the year-ago quarter.The fourth-quarter loss included stock-based compensation expenses, unrealized gain on equity securities and loss on extinguishment of debt. Excluding these items, the adjusted loss was 77 cents per share, narrower than the adjusted loss of 1.39 reported in the year-ago quart ...